Institutional shares held 1.56 Billion
28M calls
28.7M puts
Total value of holdings $78.5B
$1.4B calls
$1.44B puts
Market Cap $107B
2,126,160,000 Shares Out.
Institutional ownership 73.58%
# of Institutions 2,783


Latest Institutional Activity in BMY

Top Purchases

Q1 2025
Sg Americas Securities, LLC Shares Held: 634K ($31.8M)
Q1 2025
Achmea Investment Management B.V. Shares Held: 666K ($33.4M)
Q1 2025
Sumitomo Mitsui Trust Holdings, Inc. Shares Held: 5.04M ($253M)
Q1 2025
Vontobel Holding Ltd. Shares Held: 1.28M ($64.3M)
Q1 2025
Artemis Investment Management LLP Shares Held: 242K ($12.2M)

Top Sells

Q1 2025
Gamma Investing LLC Shares Held: 39.7K ($1.99M)
Q1 2025
Calamos Advisors LLC Shares Held: 107K ($5.37M)
Q1 2025
Wedge Capital Management L L P Shares Held: 4.01K ($202K)
Q1 2025
Teacher Retirement System Of Texas Shares Held: 975K ($49M)
Q1 2025
Envestnet Asset Management Inc Shares Held: 3.23M ($162M)

About BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.


Insider Transactions at BMY

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
361K Shares
From 15 Insiders
Exercise of conversion of derivative security 351K shares
Open market or private purchase 9.9K shares
Sell / Disposition
215K Shares
From 26 Insiders
Payment of exercise price or tax liability 120K shares
Other acquisition or disposition 94.9K shares
Open market or private sale 700 shares

Track Institutional and Insider Activities on BMY

Follow BRISTOL MYERS SQUIBB CO and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BMY shares.

Notify only if
Any

Insider Trading

Get notified when an Bristol Myers Squibb CO insider buys or sells BMY shares.

Notify only if
Any
Any
P - Open market or private purchase×
S - Open market or private sale×
V - Transaction voluntarily reported earlier than required×
A - Grant, award, or other acquisition×
D - Sale (or disposition) back to the issuer×
F - Payment of exercise price or tax liability×
I - Discretionary transaction×
M - Exercise of conversion of derivative security×
C - Conversion of derivative security×
E - Expiration of short derivative position×
H - Expiration (or cancellation) of long derivative position with value received×
O - Exercise of out-of-the-money derivative securities×
X - Exercise of in-the-money or at-the-money derivatives securities×
G - Bona fide gift×
L - Small Acquisition×
W - Acquisition or disposition by will or laws×
Z - Deposit into or withdrawal from voting trust×
J - Other acquisition or disposition×
K - Transaction in equity swap or similar instrument×
U - Disposition due to a tender of shares in a change of control transaction×
20 item(s) selected

News

Receive news related to BRISTOL MYERS SQUIBB CO

Track Activities on BMY